ERBB2 and breast cancer: A meta-analysis of 11 randomized controlled trials (RCTs) also confirmed that dual HER2 blockade is associated with higher pCR rates in nonmetastatic HER2-positive BC (OR 2.88, 95% CI: 2.02–4.10) [20].